![]() Pfizer’s recent string of patent victories came to a screeching halt yesterday when the Supreme Court rejected Pfizer’s emergency appeal on Norvasc’s patent. It was a Hail Mary shot for Pfizer and worth taking, but the outcome is not surprising. Norvasc is going generic. |
Write a comment:
|